Start here if you're new
what it is
BrainStorm is trying to turn a patient's own cells into treatments for ALS, MS, Alzheimer's, and other brain diseases.
how it gets paid
Last year Brainstorm Cell made n/a in revenue.
what just happened
The clean takeaway is simple: BrainStorm still posted an EPS loss of -$0.91 in the latest quarter, with revenue still not disclosed here.
At a glance
C+ balance sheet — struggling to keep the lights on
25/100 earnings predictability — expect surprises
-$2.31 fy2024 eps est
1.5 beta
~$8M market cap
xvary composite: 23/100 — weak
What they do
BrainStorm is trying to turn a patient's own cells into treatments for ALS, MS, Alzheimer's, and other brain diseases.
The whole story is NurOwn, a proprietary cell platform aimed at brutal diseases where patients have few options. That focus keeps the company lean at just 29 employees, which means one clinical win can matter a lot. The flip side is obvious: if your entire case rests on one platform, leaving is easy for investors and brutal for the stock.
How they make money
n/a
annual revenue
The products that matter
cell therapy candidate
NurOwn
sole value driver shown in this snapshot
it is the therapy carrying the whole $8M equity story. The page shows no firm final data date, which means time itself has become part of the risk.
binary catalyst
capital structure reality
recent financing
$2M raised in february 2026
for a stock valued at roughly $8M, a $2M raise is not background noise. It tells you funding access matters almost as much as the science.
survival math
what investors actually own
optionality
$0.53 share price · 52-week range $0–$2
this is not a compounding story today. It is a small-cap option on a single outcome, with a stock record that already tells you the path will not be smooth.
high volatility
Key numbers
$2.31
2024 EPS est.
EPS → profit per share → so what: the company is still expected to lose $2.31 a share in 2024, even after losses narrowed from -$6.00 in 2023.
$0M
TTM revenue
Revenue → money from customers → so what: there is no operating business here yet, only a clinical program looking for a path to sales.
5/100
price stability
Price stability → how calm the stock trades → so what: 5 out of 100 says you should expect violent moves, not a smooth ride.
$0M
long-term debt
Long-term debt → borrowed money due later → so what: no long-term debt helps, but zero debt does not fix zero revenue.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (1% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for BCLI right now.
source: institutional data · return history unavailable
What just happened
reported a loss
The clean takeaway is simple: BrainStorm still posted an EPS loss of -$0.91 in the latest quarter, with revenue still not disclosed here.
Quarterly losses have narrowed versus 2023, with 2024 quarterly EPS running from -$0.75 to -$0.40 in the provided history. That is progress, but the business still has $0M in trailing revenue based on consensus data.
$0M
ttm revenue
-$0.91
latest eps
379%
eps vs. last year
the number that mattered
The number that mattered was -$0.91 EPS, because in a company with $0M trailing revenue, the loss trend is still the operating story.
source: company filings and consensus data, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is NurOwn failing to produce investable data before cash needs return.
med
dilution risk is not theoretical
The company raised $2M in february 2026. On an $8M market cap, even small financings can reshape the equity story fast.
capital pressure
med
this is a one-asset story
NurOwn is the sole potential value catalyst shown on the page. If that catalyst slips or disappoints, there is no diversified business mix to cushion the blow.
concentration risk
med
trading can overwhelm fundamentals
A 5 / 100 price stability score and a quoted 52-week range of $0–$2 tell you the stock can move violently even before the core question gets answered.
volatility risk
med
reported numbers will stay noisy
An earnings predictability score of 25 / 100 means quarters are unlikely to look smooth or reassuring. You should expect event-driven swings, not clean operating trends.
reporting risk
You are not buying a business with proven sales. You are buying a $8M clinical bet with very little room for mistakes.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
march 30–31 results
Expected march 30–31, 2026. The key question is not just the reported line items. It is what the filing says about cash after the february raise.
risk
how fast the $2M gets consumed
The recent financing matters because it equals one-quarter of the current market cap. If cash burn stays heavy, more capital could arrive sooner than bulls want.
trend
whether the final NurOwn readout gets a real date
No firm date is shown. That keeps the main catalyst abstract, and abstract catalysts usually deserve a discount.
metric
price stability staying stuck at 5 / 100
That score is telling you the market already treats this as a high-volatility instrument. If the stability profile does not improve, every financing headline will hit harder.
Analyst rankings
earnings predictability
25 / 100
in human-speak, the reported numbers are likely to surprise you more than they reassure you.
balance sheet grade
C+
below average balance sheet quality. No debt problem, but funding risk is still front and center.
risk rank
5
ranks run from 1 to 5. This is the weakest bucket, with safety better than only 5% of stocks.
price stability
5 / 100
the market is telling you this one trades on event risk and liquidity, not calm institutional sponsorship.
source: institutional data
Institutional activity
institutional ownership data for BCLI is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive